SWOG clinical trial number
SWOG-9430

A Phase II Trial of Complete Surgical Resection for Stage IV Melanoma-Surgical Resection with Biological and Clinical Follow-Up

Closed
Phase
Accrual
70%
Published
Abbreviated Title
Surgical Resection for Stage IV Melanoma
Activated
11/15/1996
Closed
11/15/2005
Participants
NCORP, Members, Medical Oncologists, Surgeons, Pathologists, ECOG

Research committees

Melanoma

Treatment

Surgery

Eligibility Criteria Expand/Collapse

Stage IV (Any T, Any N, M1a or M1b) surgically deemed resectable disease; Pts must be expected to be grossly free of all known disease following surgery; Prior hormonal, RT, CT, immunotherapy allowed; PS 0-2; No evidence of metastatic disease other than the lesions planned for resection/must be confirmed by CT scans of chest, abdomen/pelvis (PET may be substituted for CT abdomen/pelvis), brain.

Publication Information Expand/Collapse

2015

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications

KF Grossmann;K Margolin Therapeutic Advances in Medical Oncology May;7(3):181-191

PMid: PMID26673806 | PMC number: PMC4406913

2011

A phase II trial of complete resection for stage IV melanoma: results of Southwest Oncology Group (SWOG) clinical trial S9430

J Sosman;J Moon;J Tuthill;J Warneke;J Vetto;BG Redman;PY Liu;J Unger;L Flaherty;V Sondak Cancer 117:4740-4746;

PMid: PMID21455999 | PMC number: PMC3129414

2006

Surgical resection for stage IV melanoma: a Southwest Oncology Group trial (S9430)

VK Sondak;PY Liu;J Warneke;J Vetto;R Tuthill;B Redman;JA Sosman Proc of the ASCO, Journal of Clinical Oncology 24(18S):#8019

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
91%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase